Activity of novel synthetic peptides against Candida albicans

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lum, Kah Yean ^a   Tay, Sun Tee ^a   Le, Cheng Foh ^b   Lee, Vannajan Sanghiran ^a   Sabri, Nadia Hanim ^a   Velayuthan, Rukumani Devi ^a   Hassan, Hamimah ^a   Sekaran, Shamala Devi ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF NOTTINGHAM MALAYSIA CAMPUS   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; PEPTIDE;

CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY; GROWTH, DEVELOPMENT AND AGING; HUMAN; SYNTHESIS;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; HUMANS; PEPTIDES;

EID: 84929192159     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09657     Document Type: Article

References (48)

1. Yapar, N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 10, 95-105 (2014).
2. Dignani, M.-C., Solomkin, J. S. & Anaissie, E. J. in Clinical Mycology 2nd edn, (eds. Anaissie, E. J., McGinnis, M. R. & Pfaller, M. A.) Ch.8, 197-229 (Churchill Livingstone, Edinburgh, 2009).
3. Sievert, D. M. et al. Antimicrobial-resistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34, 1-14 (2013).
4. Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39, 309-317 (2004).
5. Montagna, M. T. et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 41, 645-653 (2013).
6. Tang, H. J., Liu, W. L., Lin, H. L. & Lai, C. C. Epidemiology and prognostic factors of candidemia in cancer patients. PLoS One 9, e99103 (2014).
7. Pfaller, M. A. et al. Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2, 496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004-2008. PLoS One 9, e101510 (2014).
8. Tzar, M. N. & Shamim, A. S. Candidaemia and antifungal susceptibility testing in a teaching hospital. Med J Malaysia 64, 61-64 (2009).
9. Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133-163 (2007).
10. Aubron, C. et al. The epidemiology of bacteriuria and candiduria in critically ill patients. Epidemiol Infect 143, 653-662 (2014).
11. World Health Organization. Antimicrobial resistance: global report on surveillance. (2014). Available at: http://www.who.int/drugresistance/documents/ surveillancereport/en/. (Accessed on 01/12/2014).
12. Pfaller, M. A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125, S3-13 (2012).
13. Hancock, R. E. W. & Chapple, D. S. Peptide Antibiotics. Antimicrobial Agents and Chemotherapy 43, 1317-1323 (1999).
14. Hancock, R. E.&Sahl, H. G. Antimicrobial and host-defense peptides as new antiinfective therapeutic strategies. Nat Biotechnol 24, 1551-1557 (2006).
15. Reddy, K. V. R., Yedery, R. D. & Aranha, C. Antimicrobial peptides: premises and promises. International Journal of Antimicrobial Agents 24, 536-547 (2004).
16. Jenssen, H., Hamill, P. & Hancock, R. E. W. Peptide Antimicrobial Agents. Clinical Microbiology Reviews 19, 491-511 (2006).
17. Fjell, C. D., Hiss, J. A., Hancock, R. E. W. & Schneider, G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11, 37-51 (2012).
18. Podorieszach, A. P. & Huttunen-Hennelly, H. E. K. The effects of tryptophan and hydrophobicity on the structure and bioactivity of novel indolicidin derivatives with promising pharmaceutical potential. Organic & Biomolecular Chemistry 8, 1679-1687 (2010).
19. Wang, Y. et al. Design of novel analogues of short antimicrobial peptide anoplin with improved antimicrobial activity. Journal of Peptide Science 20, 945-951 (2014).
20. Thankappan, B. et al. Antimicrobial and antibiofilm activity of designed and synthesized antimicrobial peptide, KABT-AMP. Appl Biochem Biotechnol 170, 1184-1193 (2013).
21. Chia, B. C., Carver, J. A., Mulhern, T. D. & Bowie, J. H. The solution structure of uperin 3.6, an antibiotic peptide from the granular dorsal glands of the Australian toadlet, Uperoleia mjobergii. J Pept Res 54, 137-145 (1999).
22. Douglas, L. J. Candida biofilms and their role in infection. Trends Microbiol 11, 30-36 (2003).
23. Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes 1788, 1687-1692 (2009).
24. Matejuk, A. et al. Peptide-based Antifungal Therapies against Emerging Infections. Drugs Future 35, 197 (2010).
25. Asthana, N., Yadav, S. P. & Ghosh, J. K. Dissection of antibacterial and toxic activity of melittin: a leucine zipper motif plays a crucial role in determining its hemolytic activity but not antibacterial activity. J Biol Chem 279, 55042-55050 (2004).
26. Justo, J. A. & Bosso, J. A. Adverse Reactions Associated with Systemic Polymyxin Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35, 28-33 (2015).
27. Kim, H., Jang, J. H., Kim, S. C. & Cho, J. H. De novo generation of short antimicrobial peptides with enhanced stability and cell specificity. Journal of Antimicrobial Chemotherapy 69, 121-132 (2014).
28. Wieprecht, T. et al. Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. Biochemistry 36, 6124-6132 (1997).
29. Chen, Y. et al. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob Agents Chemother 51, 1398-1406 (2007).
30. Chan, D. I., Prenner, E. J. & Vogel, H. J. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochimica et Biophysica Acta (BBA) - Biomembranes 1758, 1184-1202 (2006).
31. Wang, Y. et al. Design of novel analogues of short antimicrobial peptide anoplin with improved antimicrobial activity. J Pept Sci 20, 945-951 (2014).
32. Van der Weerden, N. L., Bleackley, M. R. & Anderson, M. A. Properties and mechanisms of action of naturally occurring antifungal peptides. Cell Mol Life Sci 70, 3545-3570 (2013).
33. Matsuzaki, K. et al.Modulation of magainin 2-lipid bilayer interactions by peptide charge. Biochemistry 36, 2104-2111 (1997).
34. Ramage, G., Saville, S. P., Thomas, D. P. & Lopez-Ribot, J. L. Candida biofilms: an update. Eukaryot Cell 4, 633-638 (2005).
35. Mukherjee, P. K. & Chandra, J. Candida biofilm resistance. Drug Resistance Updates 7, 301-309 (2004).
36. Tobudic, S., Kratzer, C., Lassnigg, A. & Presterl, E. Antifungal susceptibility of Candida albicans in biofilms. Mycoses 55, 199-204 (2012).
37. Burrows, L. L. et al. Activity of novel non-amphipathic cationic antimicrobial peptides against Candida species. J Antimicrob Chemother 57, 899-907 (2006).
38. Harris, M. R. & Coote, P. J. Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents 35, 347-356 (2010).
39. Wei, G.-X. &Bobek, L. A. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. Journal of Antimicrobial Chemotherapy 53, 750-758 (2004).
40. Tavanti, A. et al. Fungicidal activity of the human peptide hepcidin 20 alone or in combination with other antifungals against Candida glabrata isolates. Peptides 32, 2484-2487 (2011).
41. Guilhelmelli, F. et al. Antimicrobial development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Frontiers in Microbiology 4, 1-12 (2013).
42. Hawrani, A., Howe, R. A., Walsh, T. R. & Dempsey, C. E. Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides. J Biol Chem 283, 18636-18645 (2008).
43. Jin, Y., Yip, H. K., Samaranayake, Y. H., Yau, J. Y. & Samaranayake, L. P. Biofilmforming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 41, 2961-2967 (2003).
44. Jin, Y., Samaranayake, L. P., Samaranayake, Y. & Yip, H. K. Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol 49, 789-798 (2004).
45. Hall, M. J., Middleton, R. F. & Westmacott, D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11, 427-433 (1983).
46. Kaur, H., Garg, A.&Raghava, G. P. PEPstr: a de novo method for tertiary structure prediction of small bioactive peptides. Protein Pept Lett 14, 626-631 (2007).
47. Momany, F. A. & Rone, R. Validation of the general purpose QUANTA H3.2/ CHARMmH force field. Journal of Computational Chemistry 13, 888-900 (1992).
48. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461 (2010).